1. Home
  2. RIGL vs LDP Comparison

RIGL vs LDP Comparison

Compare RIGL & LDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RIGL
  • LDP
  • Stock Information
  • Founded
  • RIGL 1996
  • LDP 2012
  • Country
  • RIGL United States
  • LDP United States
  • Employees
  • RIGL N/A
  • LDP N/A
  • Industry
  • RIGL Biotechnology: Pharmaceutical Preparations
  • LDP Finance Companies
  • Sector
  • RIGL Health Care
  • LDP Finance
  • Exchange
  • RIGL Nasdaq
  • LDP Nasdaq
  • Market Cap
  • RIGL 537.6M
  • LDP 628.4M
  • IPO Year
  • RIGL 2000
  • LDP N/A
  • Fundamental
  • Price
  • RIGL $29.48
  • LDP $21.75
  • Analyst Decision
  • RIGL Buy
  • LDP
  • Analyst Count
  • RIGL 5
  • LDP 0
  • Target Price
  • RIGL $38.20
  • LDP N/A
  • AVG Volume (30 Days)
  • RIGL 492.6K
  • LDP 102.5K
  • Earning Date
  • RIGL 11-04-2025
  • LDP 01-01-0001
  • Dividend Yield
  • RIGL N/A
  • LDP 7.91%
  • EPS Growth
  • RIGL N/A
  • LDP N/A
  • EPS
  • RIGL 5.43
  • LDP N/A
  • Revenue
  • RIGL $267,921,000.00
  • LDP N/A
  • Revenue This Year
  • RIGL $59.93
  • LDP N/A
  • Revenue Next Year
  • RIGL N/A
  • LDP N/A
  • P/E Ratio
  • RIGL $5.44
  • LDP N/A
  • Revenue Growth
  • RIGL 105.62
  • LDP N/A
  • 52 Week Low
  • RIGL $13.57
  • LDP $16.16
  • 52 Week High
  • RIGL $43.72
  • LDP $20.30
  • Technical
  • Relative Strength Index (RSI)
  • RIGL 46.18
  • LDP 59.56
  • Support Level
  • RIGL $29.30
  • LDP $21.30
  • Resistance Level
  • RIGL $30.94
  • LDP $21.45
  • Average True Range (ATR)
  • RIGL 1.26
  • LDP 0.18
  • MACD
  • RIGL 0.38
  • LDP 0.01
  • Stochastic Oscillator
  • RIGL 53.61
  • LDP 90.16

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

About LDP Cohen & Steers Limited Duration Preferred and Income Fund Inc.

Cohen & Steers Ltd Duration Preferred & Income Fund, Inc. is a diversified, closed-end management investment company. Its primary investment objective is high current income and capital appreciation is its secondary investment objective. The Fund invests at least its managed assets in preferred and other income securities issued by U.S. and non-U.S. companies under normal market conditions.

Share on Social Networks: